Zoono Group Limited (ZNO) AI Stock Analysis

• Market Cap: AU$20.31M
• Dividend Yield: N/A
• Average Volume (3M): 153.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: 17.41%
• EPS Growth: 67.94%
• Country: AU
• Employees: 2
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): >-0.01
• Shares Outstanding: 406,211,760
• 10 Day Avg. Volume: 257,173
• 30 Day Avg. Volume: 153,260
• PEG Ratio: 0.04
• Price to Book (P/B): 3.62
• Price to Sales (P/S): 9.30
• P/FCF Ratio: -6.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: AU$0.05 ▼(-38.75% Downside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is held down primarily by weak financial performance—deep losses, negative margins, and ongoing cash burn alongside equity erosion. Technicals also point to a weak downtrend (below key moving averages with negative MACD), partially offset by oversold RSI conditions. Valuation is difficult to support because earnings are negative and no dividend yield is provided.

Positive Factors

Low Leverage

Low financial leverage reduces immediate solvency risk and gives management time to address operating losses. With limited debt obligations Zoono has structural flexibility to raise incremental capital, invest in distribution or R&D, and avoid near-term default risk while pursuing a path to profitability.

Product-Market Focus

Zoono’s focus on antimicrobial surface and skin products targets structural demand in hygiene and infection control across consumer, institutional and commercial channels. This diversified end-market exposure supports enduring demand drivers (health, sanitation, regulatory hygiene standards) that can sustain revenue over multiple cycles.

Recent Revenue Growth

Positive top-line growth in FY2025 indicates some rebound in end-market traction and product uptake. While the base is small, durable revenue growth demonstrates the business can expand sales; sustaining and scaling this trend via channels or product mix improvements would be key to long-term recovery.

Negative Factors

Deep Negative Profitability

Extremely negative margins are structurally damaging: they erode capital, deter investors and limit reinvestment capacity. Without a credible path to positive gross and operating margins, the business will depend on external financing, which risks dilution and imperils long-term viability if profitability cannot be restored.

Persistent Cash Burn

Consistent negative operating cash flow shows the company cannot self-fund operations or growth. Ongoing cash burn increases reliance on external capital, raises refinancing and dilution risk, and constrains the ability to invest in sales, marketing, or product development needed for a sustainable turnaround.

Eroding Equity Base

Material erosion of equity over several years reduces the company’s loss-absorbing buffer and creditworthiness. A weakened capital base limits strategic flexibility, increases borrowing costs, and makes it harder to fund expansion or weather setbacks, heightening the long-term risk profile absent sustained profitability.

Zoono Group Limited Business Overview & Revenue Model

Company Description

Zoono Group Limited, together with its subsidiaries, engages in the research, development, and sale of a range of antimicrobial products in New Zealand and internationally. The company's products include hand sanitizers, textile applicators, mould remediation, and surface sanitizers. It serves airlines, healthcare, childcare, facilities management, transportation, education, and hospitality sectors. The company was incorporated in 1986 and is headquartered in Auckland, New Zealand.

How the Company Makes Money

Zoono Group Limited makes money primarily by selling Zoono-branded antimicrobial products. Revenue is generated from product sales through a mix of channels that can include direct sales to commercial/institutional customers and sales via distributors/retail or other channel partners, depending on the market. The company’s earnings are therefore driven by (1) unit volumes sold, (2) product pricing and mix across different applications (e.g., surface and hand/skin products), and (3) the breadth and effectiveness of its distribution and customer relationships in each region. More specific breakdowns of revenue streams (e.g., by geography, channel, customer segment, or named partnerships) are null.

Zoono Group Limited Financial Statement Overview

Summary

Overall fundamentals are stressed: revenue is small (~A$1.16M in FY2025) and profitability remains deeply negative (net margin ~-314%) with multi-year losses. Cash flow is persistently negative (FY2025 operating cash flow ~-A$1.58M) and equity has eroded materially over time, though low leverage (debt-to-equity ~0.18) reduces immediate solvency risk.

Income Statement

Profitability has deteriorated sharply versus earlier years. Revenue in FY2025 rose to ~A$1.16M (+14.8% YoY), but the company remains deeply loss-making with negative gross profit and very weak operating profitability (FY2025 net margin about -314%). Results have been volatile: strong profits in FY2020–FY2021 were followed by multi-year losses and structurally depressed margins, indicating an unproven path back to sustainable earnings.

Balance Sheet

Leverage is low, with FY2025 debt of ~A$0.54M against equity of ~A$2.97M (debt-to-equity ~0.18), which reduces solvency risk. However, equity has fallen materially over time (from ~A$19.6M in FY2020 to ~A$3.0M in FY2025) and returns on equity are strongly negative in recent years, reflecting ongoing losses eroding the capital base.

Cash Flow

Cash generation is weak and consistently negative. Operating cash flow was negative in each of the last four fiscal years, including ~-A$1.58M in FY2025, with free cash flow also negative and declining (~-36% YoY). While cash burn improved versus FY2024, the business is still funding operations from sources other than internally generated cash, which raises financing and dilution risk if losses persist.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	950.69K	1.16M	960.30K	3.07M	8.13M	25.22M
Gross Profit	-709.17K	-281.53K	-4.36M	-625.33K	2.10M	11.88M
EBITDA	-3.07M	-3.26M	-7.89M	-181.62K	-5.11M	5.89M
Net Income	-3.51M	-3.64M	-8.30M	-321.97K	-10.28M	4.40M
Balance Sheet
Total Assets	6.01M	5.87M	9.01M	13.40M	17.68M	29.46M
Cash, Cash Equivalents and Short-Term Investments	475.33K	47.30K	1.79M	759.99K	3.30M	4.55M
Total Debt	625.70K	544.56K	726.63K	868.99K	1.00M	1.93M
Total Liabilities	2.53M	2.89M	2.76M	3.24M	8.41M	9.88M
Stockholders Equity	3.47M	2.97M	6.24M	10.16M	10.00M	19.68M
Cash Flow
Free Cash Flow	-1.76M	-1.58M	-2.89M	-3.55M	-996.61K	834.07K
Operating Cash Flow	-1.76M	-1.58M	-2.89M	-3.55M	-974.11K	1.38M
Investing Cash Flow	0.00	0.00	-58.73K	-53.49K	-107.62K	-1.26M
Financing Cash Flow	1.50M	-190.15K	3.99M	873.62K	-54.99K	-4.82M

Zoono Group Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZNO, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and above the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.04 is Neutral, neither overbought nor oversold. The STOCH value of -11.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ZNO.

Zoono Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
SKN	45 Neutral	AU$12.00M	-0.26	2542.90%	―	12.92%	34.21%
ZNO	44 Neutral	AU$20.31M	-7.05	-108.90%	―	17.41%	67.94%
CCO	44 Neutral	AU$8.80M	-1.73	-322.76%	―	88.48%	51.61%
NGS	42 Neutral	AU$6.33M	-0.01	226.76%	―	-21.84%	79.99%

Zoono Group Limited Corporate Events

Zoono Releases Interim Financial Report for Half-Year Ended 31 December 2025

Zoono Group Limited has released its interim financial report and ASX Appendix 4D for the half-year ended 31 December 2025. The document provides condensed financial statements, directors’ commentary, auditor review information and other statutory disclosures, and is intended to be read alongside the company’s 30 June 2025 annual report and prior continuous disclosures under Australian corporate and listing regulations.

The most recent analyst rating on (AU:ZNO) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Zoono Group Limited stock, see the AU:ZNO Stock Forecast page.

Zoono Clarifies Compliance Status of Planned Share Placement in Appendix 3B Update

Zoono Group Limited has updated its previously announced proposed issue of securities, clarifying that the share recipient was not a related party or other person captured under ASX Listing Rule 10.11 when the agreement to issue the shares was made. This clarification is part of an amended Appendix 3B filing concerning a placement or other type of security issue, and is intended to confirm compliance with ASX requirements around approvals and related-party transactions, reducing potential governance concerns for investors.

The company reaffirmed that the proposed securities will be quoted on the ASX in line with standard procedures, with final issuance details to be notified once confirmed under a separate Appendix 2A. By tightening the disclosure around the nature of the recipient and regulatory treatment of the placement, Zoono aims to provide greater transparency to the market and ensure that stakeholders understand that additional shareholder approvals under Listing Rule 10.11 are not required for this transaction.

The most recent analyst rating on (AU:ZNO) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Zoono Group Limited stock, see the AU:ZNO Stock Forecast page.

Zoono Appoints New Director With Performance-Linked Share Incentive

Zoono Group Limited has appointed Marc Braterman as a director effective 3 February 2026, with disclosures confirming that he currently holds no shares or indirect security interests in the company. The filing outlines that, in his role as CEO of OSY Group Limited, Braterman has a long-term incentive arrangement granting rights to acquire up to 5 million Zoono fully paid ordinary shares at nil consideration in three performance-based tranches tied to escalating gross sales targets in New Zealand dollars, signaling a focus on growth-driven executive alignment that may influence the company’s future performance and governance dynamics.

The most recent analyst rating on (AU:ZNO) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Zoono Group Limited stock, see the AU:ZNO Stock Forecast page.